blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4041283

EP4041283 - IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  27.04.2024
Database last updated on 14.09.2024
FormerRequest for examination was made
Status updated on  15.07.2022
FormerThe international publication has been made
Status updated on  26.03.2021
Most recent event   Tooltip13.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
National Institute for Biotechnology in the Negev Ltd.
Bldg. 39
Ben Gurion University of the Negev
8410501 Beer-Sheva / IL
[2022/33]
Inventor(s)01 / PORGADOR, Angel
11 Tavlan Street
8533800 Lehavim / IL
 [2022/33]
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[2022/33]
Application number, filing date20865474.922.09.2020
[2022/33]
WO2020IL51029
Priority number, dateUS201962903855P22.09.2019         Original published format: US 201962903855 P
[2022/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021053681
Date:25.03.2021
Language:EN
[2021/12]
Type: A1 Application with search report 
No.:EP4041283
Date:17.08.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 25.03.2021 takes the place of the publication of the European patent application.
[2022/33]
Search report(s)International search report - published on:IL25.03.2021
(Supplementary) European search report - dispatched on:EP13.09.2023
ClassificationIPC:A61K38/20, A61P37/02, A61P19/02, A61K38/17, C07K14/00, A61P29/00, A61P37/00
[2023/41]
CPC:
E03F5/0404 (EP,IL,US); A61K38/1709 (EP); A61K38/2013 (EP);
A61P1/00 (US); A61P19/02 (US); A61P29/00 (EP);
A61P37/00 (EP); A61P37/06 (US); C07K14/55 (EP,US);
C07K14/705 (EP); E03F5/046 (IL,US); A61K38/00 (US);
C07K2319/00 (EP); C07K2319/21 (EP); C07K2319/31 (US);
C07K2319/50 (EP) (-)
C-Set:
A61K38/1709, A61K2300/00 (EP);
A61K38/2013, A61K2300/00 (EP)
Former IPC [2022/33]A61K38/20, A61P37/02, A61P19/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/33]
TitleGerman:CHIMÄRE IL-2 PROTEINE ZUR IMMUNSUPPRESSION[2022/33]
English:IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION[2022/33]
French:PROTÉINES CHIMÉRIQUES D'IL-2 POUR IMMUNOSUPPRESSION[2022/33]
Entry into regional phase20.04.2022National basic fee paid 
20.04.2022Search fee paid 
20.04.2022Designation fee(s) paid 
20.04.2022Examination fee paid 
Examination procedure20.04.2022Examination requested  [2022/33]
08.04.2024Amendment by applicant (claims and/or description)
08.04.2024Date on which the examining division has become responsible
29.04.2024Despatch of a communication from the examining division (Time limit: M06)
Fees paidRenewal fee
07.08.2022Renewal fee patent year 03
28.09.2023Renewal fee patent year 04
13.08.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2013140393  (YISSUM RES DEV CO [IL], et al) [A] 1-15 * the whole document *;
 [A]WO2017201432  (JOUNAIDI YOUSSEF [US], et al) [A] 1-15* the whole document *
International search[Y]WO2018011803  (NAT INST BIOTECHNOLOGY NEGEV LTD [IL], et al) [Y] 13-18,21,22* SEQ ID NO: 69; description paragraph [0273] *;
 [XY]  - WARD, N. C. et al., "IL -2/ CD 25: a long-acting fusion protein that promotes immune tolerance by selectively targeting the IL -2 receptor on regulatory T cells", The Journal of Immunology, (20181003), vol. 201, no. 9, doi:10.4049/jimmunol.1800907, pages 2579 - 2592, XP055627515 [X] 1-6,8-12,23,24,28 * whole document whole document, especially page 2590, a para bridging left and right columns * [Y] 7,13-18,21,22

DOI:   http://dx.doi.org/10.4049/jimmunol.1800907
 [Y]  - COOLES, F. A. et al., "Treg cells in rheumatoid arthritis: an update", Current rheumatology reports, (20130915), vol. 15, no. 9, XP055808707 [Y] 7 * electronic version, page 5, a para before last - page 7, 2nd para *

DOI:   http://dx.doi.org/10.1007/s11926-013-0352-0
 [Y]  - BELL, C. J. et al., "Sustained in vivo signaling by long-lived IL -2 induces prolonged increases of regulatory T cells", Journal of autoimmunity, (20150131), vol. 56, pages 66 - 80, XP029125822 [Y] 13-18,21,22 * whole document *

DOI:   http://dx.doi.org/10.1016/j.jaut.2014.10.002
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.